Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.91 -0.09 (-0.06%) Market Cap: 14.28 Bil Enterprise Value: 13.59 Bil PE Ratio: 39.09 PB Ratio: 5.98 GF Score: 89/100

Neurocrine Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 03:15PM GMT
Release Date Price: $83.93 (+3.66%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Okay, welcome to the second day of the Barclays Global Healthcare Conference. I'm Geoff Meacham. I'm the senior biopharma analyst here. And Scott Gaffner from my team is up with me on stage too. And we're thrilled to have Neurocrine Biosciences here. And on my right here is CEO, Kevin Gorman; and CFO, Matt Abernethy. Welcome, guys.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you.

Matthew C. Abernethy
Neurocrine Biosciences, Inc. - CFO

Thank you.

Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

So a lot of stuff to talk about, but maybe the most topical was the CAH data just coming out yesterday. I just want to kind of get you guys' view. Obviously, the adult data is sort of the segue into the ultimate pediatric population. But maybe kind of give us your high level. We'll get to some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot